Primary Health Properties (LON: PHP)
The NHS’s Landlord Just Got a Lot Bigger
Dear reader,
Most investors walk straight past Primary Health Properties. It doesn’t move fast, it doesn’t make headlines, and there’s no obvious story to tell at a dinner party. But it quietly does something most of the stock market can only dream of: it collects rent, mostly from the NHS, month after month, through recessions, rate cycles, and political chaos.
PHP owns the buildings where your GP works. For thirty consecutive years it has grown its dividend. But 2025 changed the company’s shape entirely. A £1.6 billion deal doubled the portfolio overnight, stretched the balance sheet, and left shareholders with a business that looks quite different from the one they bought into.
So what do you actually own now and is it worth owning?
Key Ratios:
Dividend Yield: 7.3%
Price to Net Asset Value: ~0.85x
Dividend Cover: 1.12x
Loan to Value: 57%
What PHP Actually Does (And Why It Matters)
Before we get into the numbers, it’s worth being clear about the business model, because it’s genuinely one of the more elegant structures in the UK listed space.
PHP buys and develops the buildings that GPs, NHS organisations, and other primary healthcare providers operate from. It then leases those buildings back to them on long, upwards-only leases, typically well over a decade in length. The rent is, in the vast majority of cases, funded directly or indirectly by the NHS or the Irish equivalent, the HSE. At year end, 76% of PHP’s income came from government bodies in this way.
Think about what that means in practice. PHP’s tenants aren’t independent coffee shops or discretionary retailers who might fold when the economy turns. They’re GP practices. The demand for their services goes up when times are hard, not down. Nobody stops being ill because interest rates are high.
The other thing worth understanding is the structural tailwind sitting behind this business. The NHS’s 10-year Health Plan, published in July 2025, set out an explicit ambition to shift care away from hospitals and into the community. Neighbourhood health centres. Local diagnostics. Multidisciplinary teams operating out of modern primary care facilities embedded in communities. The government is, in effect, writing PHP a very long-term business case. The problem is that much of the existing primary care estate in this country is old, cramped, and completely unfit for what the NHS now needs it to do.
PHP owns 1,142 assets. It has been doing this for three decades. It has the relationships, the development pipeline, and now after the Assura deal the scale to position itself as the partner of choice when the NHS starts seriously investing in that estate upgrade.
That’s the bull case in a sentence: a government-backed income stream, a structural growth driver baked into national health policy, and a 30-year track record of returning cash to shareholders.
Now let’s look at whether the company is actually executing against that opportunity and where the risks are hiding.
The Assura Deal
Every company calls its major acquisitions “transformational.” It’s one of those words that gets used so often in investor communications that it’s almost lost all meaning. So let’s be specific about what PHP actually did here, and whether it was the right move.
In August 2025, PHP’s offer for Assura went unconditional, with full legal completion of the final shares following in October. The deal was funded through 1.26 billion new PHP shares at a weighted average price of 93 pence each and £407 million in cash, with the cash financed through a £1.225 billion bridging loan. Total consideration came in at just over £1.6 billion.
The numbers are stark. Before the deal, PHP had a portfolio of £2.8 billion across 516 assets with a rent roll of £154 million. After it, the portfolio sits at £6 billion across 1,142 assets with a rent roll of £342 million. The company also vaulted into the top quarter of the FTSE 250, which matters more than it sounds, it brings index-tracker buying, better analyst coverage, and a lower cost of capital over time.
Assura also brought private hospitals. The enlarged group now has 33 of them worth around £700 million, representing approximately 12% of the total portfolio. The operational metrics look solid rent cover has improved to 2.8 times and rents grew 3.2% in 2025 but whether you see this as useful diversification or a distraction from PHP’s core government-backed model is a fair question.
The deal has left marks on the balance sheet. LTV has risen to 57%, above PHP’s own target range of 40–50%. Only 73% of net debt is fixed or hedged, down from 100% before the deal. And the bridging loan carries a higher margin than the group’s long-term fixed rate facilities.
Management is addressing all of this. The £103 million primary care joint venture injection, the active process to find a strategic partner for the private hospital portfolio, and the synergy delivery £7.5 million of the £9 million target already banked ahead of schedule all point to a team that knows exactly what needs to happen next.
PHP paid a full price and stretched the balance sheet to do it. The strategic logic is sound, the execution so far is encouraging, but 2026 is the year that either vindicates or complicates the whole thing.
The Numbers: What the Results Actually Tell Us
The headline figures look impressive, net rental income up 49%, adjusted earnings up 41% , but they need context before you get too excited. The 2025 results only capture 4.5 months of the combined group, because Assura didn’t contribute until mid-August. The number that actually matters for shareholders is adjusted earnings per share: 7.3 pence, up 4% on the prior year. That’s the figure that drives the dividend, and it grew despite the significant cost and distraction of completing a £1.6 billion deal. In plain terms: the acquisition paid its way from day one.
Rental growth is the part of the income story that doesn’t get enough attention. For years PHP’s portfolio was secure but the income barely moved. That’s changing. PHP delivered 3.2% rental growth in 2025, ahead of its own guidance, and the momentum carried into early 2026 with 3.4% annualised on reviews already settled. The drivers are structural, inflation feeding through into rent reviews, higher building costs creating new benchmarks, and a systematic programme of lease renewals and refurbishments across the portfolio. On a £342 million rent roll with near-zero vacancy, 3–4% annual growth compounds into materially higher earnings over time. This is the part of the PHP story that has genuinely improved.
Costs are a quiet strength. PHP runs one of the leanest operations in the UK REIT sector, with an EPRA cost ratio of 9.8%. With £7.5 million of the £9 million Assura synergy target already banked, that ratio is heading toward 9% in 2026. For income investors this matters more than it sounds, lower costs mean more of the rent roll flows through to earnings and dividend cover.
The balance sheet is the part that requires the most scrutiny. PHP borrowed heavily to do this deal, and the numbers reflect it. Net debt stands at £3.4 billion, LTV is at 57% against a self-imposed target of 40–50%, and interest cover has slipped from 3.1 to 2.8 times. None of these figures are at distress levels, the banks are comfortable, covenants are intact, but they leave PHP with less room for error than it has historically maintained. On asset value, the EPRA NTA per share fell 4% to 99 pence, largely because of transaction costs and the mechanics of the share exchange. PHP trades at roughly book value today, which is where a quality income stock with a stretched balance sheet tends to sit until the market sees the leverage coming down.
The dividend is what most investors own this stock for, so let’s be direct about it. The 7.1 pence per share paid in 2025 was fully covered by adjusted earnings, 112% cover, and management has already announced a 3% increase for 2026, marking 30 consecutive years of dividend growth. The risk is not that PHP cuts the dividend tomorrow. The risk is that until the private hospital joint venture and the primary care injection complete, capital is constrained and the margin of safety is thinner than usual. Get those transactions done at good prices in 2026, and the balance sheet concern fades into the background. Delay them, or accept a poor price under pressure, and the questions get harder to dismiss.
Valuation:
PHP’s share price has had a tough couple of years. Rising interest rates hammered all long-duration income stocks, and issuing over a billion new shares to fund the Assura deal has weighed on the price further. The result is that PHP currently trades at a noticeable discount to the value of its own assets, which is where things get interesting.
